Efficacy of a tailored approach with nivolumab (N) and nivolumab plus ipilimumab (N plus I) as immuno-therapeutic boost in metastatic urothelial carcinoma (mUC): Final results of TITAN-TCC

被引：0
|
作者：
Grimm, M-O. [1 ]
Schostak, M. [2 ]
Gruen, C. B. [3 ]
Loidl, W. C. [4 ]
Pichler, M. [5 ]
Zimmermann, U. [6 ]
Schmitz-Draeger, B. J. [7 ]
Steiner, T. [8 ]
Roghmann, F. [9 ]
Niegisch, G. [10 ]
Schmitz, M. [11 ]
Baretton, G. [12 ]
Leucht, K. [1 ]
Schumacher, U. [13 ]
Foller, S. [14 ]
Zengerling, F. [15 ]
Meran, J. [16 ]
机构：
[1] Friedrich Schiller Univ Jena, Jena Univ Hosp, Dept Urol, Jena, Germany
[2] Magdeburg Univ Hosp, Dept Urol, Magdeburg, Germany
[3] Natl Ctr Tumor Dis, Dept Med Oncol, Heidelberg, Germany
[4] Elisabethinen Hosp, Dept Urol, Linz, Austria
[5] Graz Univ Hosp, Dept Oncol, Graz, Austria
[6] Greifswald Univ Hosp, Dept Urol, Greifswald, Germany
[7] St Theresien Krankenhaus, Urol 24, Nurnberg, Germany
[8] Helios Hosp Erfurt, Dept Urol, Erfurt, Germany
[9] Univ Hosp Ruhr Univ Bochum, Marien Hosp Herne, Dept Urol, Herne, Germany
[10] Heinrich Heine Univ Dusseldorf, Dusseldorf Univ Hosp, Dept Urol, Dusseldorf, Germany
[11] Tech Univ Dresden, Fac Med Carl Gustav Carus, Inst Immunol, Dresden, Germany
[12] Tech Univ Dresden, Fac Med Carl Gustav Carus, Inst Pathol, Dresden, Germany
[13] Friedrich Schiller Univ Jena, Jena Univ Hosp, Ctr Clin Studies, Jena, Germany
[14] Friedrich Schiller Univ Jena, Jena Univ Hosp, Dept Urol, Jena, Germany
[15] Ulm Univ Hosp, Dept Urol, Ulm, Germany
[16] Hosp Barmherzige Brueder, Dept Internal Med Hematol & Internal Oncol, Vienna, Austria
来源：
ANNALS OF ONCOLOGY | 2023年 / 34卷
关键词：
D O I：
10.1016/j.annonc.2023.09.1021
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
2372P
引用
收藏
页码：S1207 / S1208
页数：2
相关论文
共 50 条
  • [1] Efficacy of a tailored approach with nivolumab and nivolumab/ipilimumab as immunotherapeutic boost in metastatic renal cell carcinoma: Final results of TITAN-RCC
    Grimm, M-O.
    Esteban Gonzalez, E.
    Barthelemy, P.
    Schmidinger, M.
    Busch, J.
    Perez Valderrama, B.
    Charnley, N.
    Schmitz, M.
    Schumacher, U.
    Baretton, G.
    Duran Martinez, I.
    De Velasco Oria, G. A.
    Priou, F.
    Maroto Rey, J. P.
    Albiges, L.
    ANNALS OF ONCOLOGY, 2022, 33 (07) : S1206 - S1207
  • [2] Nivolumab plus Ipilimumab as Immunotherapeutic Boost in Metastatic Urothelial Carcinoma A Nonrandomized Clinical Trial
    Grimm, Marc-Oliver
    Schostak, Martin
    Gruen, Christine Barbara
    Loidl, Wolfgang
    Pichler, Martin
    Zimmermann, Uwe
    Schmitz-Draeger, Bernd
    Steiner, Thomas
    Roghmann, Florian
    Niegisch, Guenter
    Bolenz, Christian
    Schmitz, Marc
    Baretton, Gustavo
    Leucht, Katharina
    Schumacher, Ulrike
    Foller, Susan
    Zengerling, Friedemann
    Meran, Johannes
    JAMA ONCOLOGY, 2024, 10 (06) : 755 - 764
  • [3] Ipilimumab challenge/re-challenge in metastatic urothelial carcinoma (mUC) and other genitourinary (GU) tumors treated with cabozantinib plus nivolumab (CaboNivo) or cabozantinib plus nivolumab plus ipilimumab (CaboNivoIpi).
    Niglio, Scot Anthony
    Girardi, Daniel Motta
    Mortazavi, Amir
    Lara, Primo
    Pal, Sumanta K.
    Saraiya, Biren
    Cordes, Lisa M.
    Ley, Lisa
    Ortiz, Olena Sierra
    Cadena, Jacqueline
    Diaz, Carlos
    Bagheri, Mohammadhadi H.
    Steinberg, Seth M.
    Costello, Rene
    Streicher, Howard
    Wright, John
    Parnes, Howard L.
    Ning, Yang-Min
    Bottaro, Donald P.
    Apolo, Andrea B.
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [4] Nivolumab plus ipilimumab (N plus I) for potentially resectable hepatocellular carcinoma (HCC): Efficacy and surgical outcome
    Su, Yung-Yeh
    Lin, Yih-Jyh
    Hsiao, Chin-Fu
    Ou, Da-Liang
    Chen, San-Chi
    Wang, Hung-Wei
    Wang, Jing-Houng
    Wu, Yao-Ming
    Lee, Wei-Chen
    Chou, Shu-Cheng
    Ho, Ching-Liang
    Chiu, Chang-Fang
    Chen, Li-Tzong
    Shen, Yen-Shan
    Cheng, Ann-Lii
    Hsu, Chiun
    ANNALS OF ONCOLOGY, 2023, 34 : S1390 - S1390
  • [5] Final results of a phase I study of cabozantinib (cabo) plus nivolumab (nivo) and cabonivo plus ipilimumab (Ipi) in patients (pts) with metastatic urothelial carcinoma (mUC) and other genitourinary (GU) malignancies
    Nadal, R.
    Mortazavi, A.
    Stein, M.
    Pal, S. K.
    Davarpanah, N.
    Parnes, H. L.
    Ning, Y. M.
    Cordes, L. M.
    Lin, J.
    Bagheri, M.
    Linderberg, L.
    Berniger, M.
    Steinberg, S. M.
    Moore, T.
    Lancaster, T.
    Aviles, M.
    Costello, R.
    Bottaro, D. P.
    Dahut, W. L.
    Apolo, A. B.
    ANNALS OF ONCOLOGY, 2017, 28
  • [6] Tailored immunotherapy approach with nivolumab with or without nivolumab plus ipilimumab as immunotherapeutic boost in patients with metastatic renal cell carcinoma (TITAN-RCC): a multicentre, single-arm, phase 2 trial
    Grimm, Marc -Oliver
    Esteban, Emilio
    Barthelemy, Philippe
    Schmidinger, Manuela
    Busch, Jonas
    Valderrama, Begona P.
    Charnley, Natalie
    Schmitz, Marc
    Schumacher, Ulrike
    Leucht, Katharina
    Foller, Susan
    Baretton, Gustavo
    Duran, Ignacio
    de Velasco, Guillermo
    Priou, Frank
    Maroto, Pablo
    Albiges, Laurence
    LANCET ONCOLOGY, 2023, 24 (11): : 1252 - 1265
  • [7] Results of phase I plus expansion cohorts of cabozantinib (Cabo) plus nivolumab (Nivo) and CaboNivo plus ipilimumab (Ipi) in patients (pts) with with metastatic urothelial carcinoma (mUC) and other genitourinary (GU) malignancies.
    Nadal, Rosa Maria
    Mortazavi, Amir
    Stein, Mark
    Pal, Sumanta K.
    Davarpanah, Nicole N.
    Parnes, Howard L.
    Ning, Yang-Min
    Cordes, Lisa M.
    Bagheri, Mohammadhadi H.
    Lindenberg, Liza
    Thompson, Ryan
    Steinberg, Seth M.
    Moore, Tina
    Lancaster, Tiffany
    Velez, Milisyaris
    Mena, Esther
    Costello, Rene
    Bottaro, Donald
    Dahut, William L.
    Apolo, Andrea B.
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (06)
  • [8] Clinical efficacy of cabozantinib plus nivolumab (CaboNivo) and CaboNivo plus ipilimumab (CaboNivoIpi) in patients (pts) with chemotherapy-refractory metastatic urothelial carcinoma (mUC) either naive (n) or refractory (r) to checkpoint inhibitor (CPI)
    Nadal, Rosa
    Mortazavi, Amir
    Stein, Mark N.
    Pal, Sumanta K.
    Lee, Daniel K.
    Parnes, Howard L.
    Ning, Yang-Min
    Cordes, Lisa M.
    Bagheri, Mohammadhadi H.
    Thompson, Ryan
    Mayfield, Christian
    Steinberg, Seth M.
    Monk, Paul
    Lara, Primo
    Costello, Rene
    Agarwal, Piyush K.
    Bottaro, Donald
    Dahut, William L.
    Apolo, Andrea B.
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [9] Nivolumab Alone and With Ipilimumab in Previously Treated Metastatic Urothelial Carcinoma: CheckMate 032 Nivolumab 1 mg/kg Plus Ipilimumab 3 mg/kg Expansion Cohort Results
    Sharma, Padmanee
    Siefker-Radtke, Arlene
    de Braud, Filippo
    Basso, Umberto
    Calvo, Emiliano
    Bono, Petri
    Morse, Michael A.
    Ascierto, Paolo A.
    Lopez-Martin, Jose
    Brossart, Peter
    Rohrberg, Kristoffer
    Mellado, Begona
    Fischer, Bruce S.
    Meadows-Shropshire, Stephanie
    Saci, Abdel
    Callahan, Margaret K.
    Rosenberg, Jonathan
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (19) : 1608 - 1616
  • [10] A pooled meta-analysis of salvage nivolumab/ipilimumab (N plus I) after nivolumab (N) in patients with advanced renal cell carcinoma (RCC)
    Mckay, R. R.
    Xie, W.
    Leucht, K.
    Jegede, O.
    Braun, D. A.
    Atkins, M. B.
    Grimm, M-O.
    Choueiri, T. K.
    ANNALS OF ONCOLOGY, 2023, 34 : S1017 - S1018
12345